GameStop Corp. (GME), Pfizer Inc. (PFE) and More: iShares Bolsters Factor ETF Lineup With 5 New Funds

Page 1 of 2

BlackRock, Inc. (BLK)BlackRock, Inc. (NYSE:BLK) iShares unit, the world’s largest ETF issuer, added to its lineup of factor-driven ETFs today with the debut of five new funds. Two of the new ETFs are managed using BlackRock, Inc. (NYSE:BLK)¬†research rather than tracking an index while the other three are iShares MSCI Factor ETFs, which seek to track MSCI Risk Premia Indices.

The new iShares factor ETFs, both of which are actively managed are the iShares Enhanced U.S. Large-Cap (NYSEARCA:IELG) and the iShares Enhanced U.S. Small-Cap (NYSEARCA:IESM).

“The new funds utilize the pioneering research on factor investing and expertise in risk management of BlackRock, Inc. (NYSE:BLK)¬†rather than tracking an index or individual stock picking. The iShares Enhanced ETFs seek to provide competitive risk-adjusted returns compared to the broad large-cap or small-cap market,” said iShares in a statement.

The iShares Enhanced U.S. Large-Cap ETF, which has an annual expense ratio of 0.18 percent, paltry by the standards of many actively managed ETFs, is home to 110 stocks. The fund’s top-10 holdings account for just 20.7 percent of the fund’s weight. IELG’s top holdings include GameStop Corp. (NYSE:GME), Pfizer Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ) and, Inc. (NASDAQ:AMZN).

The iShares Enhanced U.S. Small-Cap ETF is home to 263 stocks and charges an annual fee of 0.35 percent. That new ETF’s top-10 holdings represent just over 20 percent of the fund’s total weight. Top holdings include World Acceptance Corp. (NASDAQ:WRLD), Buffalo Wild Wings (NASDAQ:BWLD) and Arbitron Inc. (NYSE:ARB).

In addition to IELG and IESM, iShares also introduced three other factor-driven ETFs today.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!